Winship Cancer Institute of Emory University has agreed to partner with Australian-based Telix Pharmacueticals (TLX) on the development of a diagnostic and therapeutic product line based on targeted radiopharmaceuticals or “molecular-targeted radiation” (MTR).
The Clinical Trial
Enabled by a $3.5 million (US) grant by the National Institutes of Health (NIH), the study team will utilize positron emission topography (PET) imaging with FDA approved fluciclovine (Azumin®) or Telix’s investigational Ga-PSMA kit, marketed as illumet™ in the United States.
The Phase II study will prospectively evaluate 140 prostate cancer patients who are eligible for radiation therapy post-prostatectomy. The trial randomizes the two different imaging techniques with the goal of determining the degree to which either imaging approach guides radiotherapy decisions, and whether there are improvements in outcome. The study lasts until 2025.
Texlix Pharmaceuticals Ltd. Background
A global biopharmaceutical company based in Australia, the company is focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecular-targeted radiation” (MTR). With headquarters in Australia, they operate in Brussels (EU), Kyoto (JP) and Indianapolis (US). They are developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.
Their pipeline includes a renal product in Phase III and prostate cancer imaging product in Phase IIa. Their brain cancer product is also in Phase IIa. Like many biomed ventures they operate at a considerable loss—we include a link to their financials.
Ashesh Jani, MD, Radiologist Emory
David Schuster, MD, nuclear medicine physician